Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pha...
Established in 2007, and headquartered in Wakef...
Anixa is focused on harnessing the bodyâs immune system in the fight against can...
Anixa is focused on harnessing the bodyâs imm...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company i...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage...
Tricida, Inc. , Tricida, Inc. , is a pharmaceutical company focused on the develop...
Tricida, Inc. , Tricida, Inc. , is a pharmaceut...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Motif Bio is a clinical stage biopharmaceutical company developing novel antibioti...
Motif Bio is a clinical stage biopharmaceutical...
Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...
Headquartered in New York, BeyondSpring Inc. (B...
Join the National Investor Network and get the latest information with your interests in mind.